Wealth Enhancement Advisory Services LLC Has $3.24 Million Stock Holdings in Sanofi (NASDAQ:SNY)

Wealth Enhancement Advisory Services LLC cut its holdings in Sanofi (NASDAQ:SNY - Free Report) by 21.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 58,380 shares of the company's stock after selling 15,982 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Sanofi were worth $3,238,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in SNY. Lee Danner & Bass Inc. acquired a new stake in shares of Sanofi in the fourth quarter worth $31,000. Bessemer Group Inc. lifted its stake in shares of Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after buying an additional 242 shares during the last quarter. UMB Bank n.a. lifted its stake in shares of Sanofi by 30.7% in the first quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock worth $62,000 after buying an additional 264 shares during the last quarter. Whipplewood Advisors LLC acquired a new stake in shares of Sanofi in the fourth quarter worth $76,000. Finally, AdvisorNet Financial Inc lifted its stake in shares of Sanofi by 16.4% in the first quarter. AdvisorNet Financial Inc now owns 1,613 shares of the company's stock worth $89,000 after buying an additional 227 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Performance

Sanofi stock traded down $0.52 on Friday, hitting $47.85. The company's stock had a trading volume of 2,683,472 shares, compared to its average volume of 2,351,492. The firm has a market cap of $117.35 billion, a P/E ratio of 17.09, a price-to-earnings-growth ratio of 0.99 and a beta of 0.50. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16. The company has a fifty day moving average price of $50.95 and a 200-day moving average price of $52.02. Sanofi has a one year low of $45.80 and a one year high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.04. The firm had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The business's revenue for the quarter was down 11.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.78 EPS. On average, equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which was paid on Thursday, June 12th. Shareholders of record on Friday, May 9th were issued a $2.0369 dividend. This represents a yield of 3.1%. The ex-dividend date was Friday, May 9th. This is a positive change from Sanofi's previous annual dividend of $1.48. Sanofi's payout ratio is 57.14%.

Analyst Ratings Changes

SNY has been the subject of a number of analyst reports. The Goldman Sachs Group initiated coverage on shares of Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective for the company. Guggenheim restated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. BNP Paribas started coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 target price on the stock. Finally, Morgan Stanley set a $56.00 target price on shares of Sanofi in a research report on Monday, June 2nd. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $61.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.